Antares Pharma Announces Availability of OTREXUP Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis in Children

Antares Pharma (NASDAQ: ATRS ) today announced the availability of OTREXUP™, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly